All Articles

Judging by the topics covered, there is no shortage of new therapies in development.
Novel compounds of all sorts, from anti-inflammatories to receptor inhibitors, are on the way.
Simple attributes, such as how much drug can reach its target and how long it stays there, make a big difference in outcomes.
DEXTENZA successfully met primary endpoint for treatment of ocular itching associated with allergic conjunctivitis
Thinking of getting involved in a clinical trial? Here is some food for thought to help you make an informed decision.
The New Balance Reach The Beach (RTB) Relay is one of the oldest and longest running relay races in the United States.
Among chronic diseases, allergy is documented as the fifth leading group affecting 50 million Americans.
It’s prime allergy season: Here’s a primer on what to advise patients with an itch to ditch.
A look at the science behind the development of lifi tegrast, and where it fi ts into the therapeutic puzzle.